Chronic Kidney Disease covers a spectrum of renal diseases and the myriad adverse effects associated with the disease. This includes Diabetic Kidney Disease, End Stage Renal Disease, Acute Kidney Injury, Primary Hyperoxaluria, and rare glomerular diseases such as Lupus Nephritis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, C3 Glomerulopathy, Membranous Nephropathy, Polycystic disease, and Alport syndrome. Therapies are generally targeted at treating the underlying cause of CKD (diabetes, autoimmune disorder, etc.), lowering blood pressure, preventing cardiovascular as well as other complications arising from dialysis, and managing complications of CKD and dialysis including Renal Anemia, Hyperkalemia, Hyperphosphatemia, Secondary Hyperparathyroidism, and Metabolic Acidosis.
CKD is a chronic condition requiring long-term treatment to slow decline over time, however recent approvals have given the field the first new therapies in over 20 years.
Medical Conference Coverage
CardioVascular Resource Group (CVrg) is a team of expert analysts who rigorously evaluate the latest new data releases, corporate reports, and news to distill important advances in complex therapeutic areas. Our comprehensive medical congress coverage and continuous market surveillance put these advances into the context of the overall chronic kidney disease competitive landscape to help guide strategic and tactical commercial development decisions for our clients.
